MERIBEL

orange__line

Official Title: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment.

A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.

Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage.

The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.


MERIBEL at clinicaltrials.gov
TUMOR TYPE PHASE N SITES COUNTRY STATUS
Breast (Her2-) II 53 13 Spain, Portugal Accrual finalized

ESMO 2016 – Download the abstract      SABCS 2014 – Download the abstract